EUVIMEDEUVIMED entdecken
Multizentrische Studie

Recent advances in the treatment strategy for AAV improved outcomes with intensive GC tapering

Nobuyuki Ono iD, Tatsuya Kai, Yukiko Takeyama, Yasushi Inoue, Naoyasu Ueda, Shuji Nagano, Shunichiro Ohta, Hisako Inoue, Takuya Sawabe, Yutaka Chifu, Seiji Yoshizawa, Kensuke Oryoji und 10 weitere

International Journal of Rheumatic Diseases · 2024

DOI: 10.1111/1756-185x.15009 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Nobuyuki Ono und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Rheumatology/Infectious Disease, Kyushu University Hospital, Fukuoka, Japan. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Granulomatosis with Polyangiitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate trends in results of care and management for antineutrophil cytoplasmic antibodies (ANCA)‐associated vasculitis (AAV).

Methods

We employed multicenter cohort data collected during 2011–2021, recruiting 43 patients with granulomatosis with polyangiitis (GPA) and 91 with microscopic polyangiitis (MPA). According to the median registration date of September 2015, patients have split into two groups: an early group and a late group (both of them, n = 67). To prevent bias, a propensity score according to numerous baseline characteristics variables was calculated; 50 matching members of each group were statistically extracted. Their treatments and clinical outcomes were examined at 6, 12, and 24 months after initial remission therapy.

Results

Statistics demonstrated that the baseline characteristics were similar. The late group used rituximab (RTX) more often for both remission induction and maintenance therapy, compared with the early group. The mean daily PSL doses of the late group were significantly lower than those of early group at each time point. The late group discontinued PSL 14.0% at 12 months and 23.3% at 24 months. Despite their intensive glucocorticoids (GC) tapering, the remission rates and the relapse rates were significantly fairer in the late group. The Vasculitis Damage Index (VDI) and VDI due to GC at each time point were lower in the late group, and those differences had become wider over time.

Conclusion

Recent developments in AAV treatment have allowed efficient remission and prevention of relapses, which in turn enabled extensive GC tapering causing fewer sequelae.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMicroscopic PolyangiitisGranulomatosis with PolyangiitisHumansGlucocorticoidsTreatment OutcomeRituximabAntibodies, Antineutrophil CytoplasmicRemission Induction

Stichwörter der Autor:innen

ANCAANCA-associated vasculitisglucocorticoidrituximabvasculitis

Substanzen

GlucocorticoidsRituximabAntibodies, Antineutrophil Cytoplasmic

Autor:innen und Institutionen

  • Department of Clinical Immunology and Rheumatology/Infectious Disease, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Medicine and Biosystem Science, Graduate School of Medical Science, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
  • Department of Rheumatology, Saga University Hospital, Saga, Japan.
  • Department of Rheumatology, Fukuoka Red Cross Hospital, Fukuoka, Japan.
  • Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
  • Department of Rheumatology, Iizuka Hospital Iizuka Hospital, Fukuoka, Japan.

ORCID-Profile: Nobuyuki Ono, Yojiro Arinobu

Zitieren

APA

Ono, N., Kai, T., Takeyama, Y., Inoue, Y., Ueda, N., Nagano, S., Ohta, S., Inoue, H., Sawabe, T., Chifu, Y., Yoshizawa, S., Oryoji, K., Kimoto, Y., Miyake, K., Ayano, M., Mitoma, H., Arinobu, Y., Miyamura, T., Horiuchi, T., …, & Niiro, H. (2024). Recent advances in the treatment strategy for AAV improved outcomes with intensive GC tapering. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15009

Vancouver

Ono N, Kai T, Takeyama Y, Inoue Y, Ueda N, Nagano S, et al. Recent advances in the treatment strategy for AAV improved outcomes with intensive GC tapering. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15009

BibTeX
@article{Ono2024,
  author = {Ono, Nobuyuki and Kai, Tatsuya and Takeyama, Yukiko and Inoue, Yasushi and Ueda, Naoyasu and Nagano, Shuji and Ohta, Shunichiro and Inoue, Hisako and Sawabe, Takuya and Chifu, Yutaka and Yoshizawa, Seiji and Oryoji, Kensuke and Kimoto, Yasutaka and Miyake, Katsuhisa and Ayano, Masahiro and Mitoma, Hiroki and Arinobu, Yojiro and Miyamura, Tomoya and Horiuchi, Takahiko and Akashi, Koichi and Tada, Yoshifumi and Niiro, Hiroaki},
  title = {Recent advances in the treatment strategy for AAV improved outcomes with intensive GC tapering},
  journal = {International Journal of Rheumatic Diseases},
  year = {2024},
  doi = {10.1111/1756-185x.15009}
}
Kostenlos starten →